

SASTASUNDAR VENTURES LIMITED

Azinganj House, 2nd floor,
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),
Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335
Email: info@sastasundar.com; Website: www.sastasundarventures.com
CIN: L65993WB1989PLC047002

Date: 18-07-2023

To
The General Manager
Department of Corporate Services
BSE Limited
(Designated Stock Exchange)
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Ref: BSE Scrip Code: 533259; NSE Symbol: SASTASUNDR
Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached herewith the Investor Presentation of the Company.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Sastasundar Ventures Limited**

Pratap Singh
Company Secretary

Encl: As Above



“Digital Platform of Pharma Supply Chain and Diagnostic providing access of quality healthcare for all”


Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



In this digital age, we have an opportunity to transform the lives of people in ways that were hard to imagine in the past. I see technology as a means of empowerment and as a tool that bridges the distance between hope and opportunity in this digital age.



Shri Narendra Modi
Hon'ble Prime Minister of India

Management Commentary



Dear Shareholders,

We are pleased to announce that our revenue from operations grew by 66.4% for FY 2022-23 and the Gross Margin has improved to 7.4% with continuous focus on cost optimisation, process improvement and digital technology.

During the quarter ended March 2023, the revenue has increased by 97.7% as compared with quarter ended March 2022 (YOY).

We have started operations at 4 new fulfilment centers (FC's) during the year. At present we have 7 operating FC's.

We always built business on the core strength of "Efficiency" and never chase a model which runs on the strength of capital.

Our Board of Directors at its meeting held on 27th March, 2023 and 14th July, 2023 approved a Composite Scheme of Arrangement (the Scheme) for Demerger and Amalgamation amongst Sastasundar Ventures Limited ('Demerged Company' or 'Amalgamated Company') and Microsec Resources Private Limited ("Resulting Company") and Sastasundar Healthbuddy Limited ("Amalgamating Company") under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013 and the rules made there under, with effect from 1st April, 2023 ("the Appointed Date"). The scheme is subject to requisite approvals of the concerned regulatory authorities. Our objective is to eliminate the Holding CIC structure and directly list the business entities.

B. L. Mittal
(Founder & Executive Chairman)

Ravi Kant Sharma
(Founder & CEO)

Significant Play in Indian ePharma & Pharma eDistribution — High Growth Sectors



- Strategic Partnership with Flipkart



- eB2B platform distributing pharma and other healthcare products to Pharmacies & other Retailers

- D2C diagnostic services



- In process to launch eHealth app “Genu Health” centred around preventive care, diagnostic services, management of surgery and hospital care, health/disease related contents & speciality eClinic

ePharma

- Market size US\$345 mn in 2021 ¹
- To grow at CAGR of 22%

Indian Pharma Market (IPM)

- Market size US\$ 24 bn ²
- To grow at CAGR of 12%

Diagnostic

- Market size estimated US\$ 13 bn in 2023 (US\$ 10 bn in FY 2021) ³
- To grow at CAGR of 14%

Source : 1. Netscribes Industry Report
2. IBEF
3. Business Today

Digital Platform of Healthcare



B2C Platform

Pharmacy and
Wellness



B2B Platform

Pharmaceuticals
& Other
Healthcare
Products



Diagnostic
Services

Strategic partnership built on strong capabilities



75.10%
stake

- Large consumer base
- Established consumer tech capabilities
- Huge brand patronage – (Only vertical of Flipkart group using Flipkart brand)



24.90%
stake

- Most efficient supply chain & fulfilment capabilities
- Direct procurement relationship with 250+ Pharma Companies



- Managing 1800+ Pharma Companies products

Moving towards one of the leading position in ePharma

Pharma eDistribution – Digital Supply Chain of Pharmaceuticals & Other Healthcare Products

- Digital Supply Chain poised to transform the Indian Pharma distribution benefiting everyone with Pharma Companies major beneficiary
 - Improved Business Forecasting
 - Inventory Optimisation
 - Enhanced Consumer Insights
 - End to end visibility of Supply Chain
- Structural shift undergoing
 - Pharma Companies increasing reliance on industry players like SastaSundar for distribution
 - Retail Pharmacies increasing trust on eB2B platform like RetailerShakti for their procurement

Digital supply chain can lower procurement cost by 20%, reduce supply chain process costs by 50% and increase revenue by 10%.

- Study by Centre for Global Enterprise (CGE) research

~ 7 % market share of Sastasundar group in IPM in West Bengal – Validation of Structural shift

Structural Shift – Consolidation on way in Indian Pharma Distribution

Pharmaceutical wholesaling/distribution is highly consolidated industry in most of the developed countries (period last 2 to 3 decades).

In USA, 92% of the market is with 3 companies

MCKESSON

Market Cap \$54 bn

Revenue \$272 bn



Market Cap \$20 bn

Revenue \$181 bn

AmerisourceBergen

Market Cap \$33 bn

Revenue \$238 bn

India to witness similar consolidation in Pharmaceutical distribution with fewer having majority of \$24 bn Indian Pharma Market that is expected to grow @12% CAGR

India
Highly fragmented
~65k Distributors

Sastasundar group is No 1 pharma distributor in West Bengal

USA
92% Market

Top 3 Distributors

Japan
90% Market

Top 4 Distributors

Germany
70% Market

Top 3 Distributors

Australia
90% Market

Top 3 Distributors

Saudi Arabia
85% Market

Top 10 Distributors


Benefitting Pharma & FMCG Cos.

- End to End tracking of Inventory up to Retailers with real time data
- Better managed inventory leading to reduced return of expired stocks
- Better production and distribution planning
- New drugs can be introduced faster
- Huge scope for Pharma Companies for their trade generic portfolio
- Retailers can be engaged in auto pilot mode
- International standard of Warehousing and Logistics
- Credit is more secured and managed efficiently
- Sales force is optimized and Logistics cost minimised

Benefitting Retailers - Transforming Economics & Lives of Retailers

	Traditional Distributors	Benefits to Retailers
<ul style="list-style-type: none"> • Full visibility of Inventory online • 100% fulfilment • Next Day Delivery at One Click 	<ul style="list-style-type: none"> • Sourcing from Multiple Distributors • Fulfilment gaps 	<ul style="list-style-type: none"> • Reduction of Inventory Lead Time • Lower Working Capital requirement • Higher ROCE
<ul style="list-style-type: none"> • Transparent Pricing and Offers 	<ul style="list-style-type: none"> • Pricing and offers are not transparent. 	<ul style="list-style-type: none"> • Higher Margins • Automated Procurement • Saving in Time & Cost
<ul style="list-style-type: none"> • Full Tracking of Supply Chain from manufacturer to last mile 	<ul style="list-style-type: none"> • No Tracking of Supply Chain 	<ul style="list-style-type: none"> • 100% Genuine Products

Empowering Retailers – One Stop eProcurement Solution



Widest Availability and Fulfilment of Products (65000+ Products)



100% Genuine Products



High Margins with Transparent Pricing



Automated Procurement



Timely Delivery



Clear Return Policy



Snapshot

Genu Path Labs, an NABL ACCREDITED LAB, where everything revolves around Meticulous Assay of Quality Evidence. Highly experienced Clinical Team, Advanced High End Lab Equipment, Stringent Quality Norms – EQAS, ILC, Strong Process Control (QuaGen^{LR}) – we employ all of these at Genu Path Labs to ensure Accurate Test Results.

Services Offered:

Pathology Test • USG • Digital X-Ray • ECG TMT • Doppler • Holter • PFT • Echocardiography

Advanced Automated Equipment used at Genu Path Labs



35+

Sample Collection Centres across West Bengal

01


Central LAB at Newtown, Rajarhat, Kolkata

01

Satellite Lab at Balurghat, West Bengal

GENU Health app - Under making of Powerful Health Solutions

- Direct service to the consumers from Genu Path Labs as D2C Brand offering diagnostic services with seamless integration of technology
- Centred around preventive care, diagnostic services, management of surgery and hospital care, health/disease related contents & speciality eClinic
- Targeting leadership in Eastern India
- Leveraging opportunity arising out of value transition from unorganised to organised player with focus on Tier II and III cities
- Connect all stakeholders involved in healthcare deliveries e.g. doctors, hospitals, healthcare service provider.
- Facilitate digital health records and data analysis
- Utilize AI/ML- based predictive and clinical decision support system
- Provide an ecosystem of longevity – to assist customers in building Good Health Habits for Healthy Long life
- Integrate with Flipkart health+ for diagnostic services



Sastasundar Group – Value Proposition



- Best in class Customer Experience driven by Value Pricing, Quality and Tech
- Clear visibility of high growth with EBITDA + model
- Capital efficient with high ROCE
- Strong MOAT
 - Established Business Technology with highly efficient supply chain
 - Managing 1800+ Pharma Companies Product with Direct procurement relationship of 250+ Companies
 - 29% + Pharma Procurement Margin
 - Experienced team driven by processes
- Co-creating value with Flipkart Health +
- Well qualified, experienced and entrepreneurial Board and Senior Leadership Team
- Purpose and value driven organization
- Best Corporate Governance practices

Experienced Board of Directors



Mr. B L Mittal

**Founder & Executive Chairman
(Sastasundar Healthbuddy Ltd)**

- FCA, FCS and FCM by education and has an experience of more than 20 years working as an entrepreneur and a social worker.
- Areas of work include digital platform of healthcare and financial services.



Mr. Ravi Kant Sharma
Founder & CEO (Sastasundar Healthbuddy Ltd)

- FCA by education and is a seasoned entrepreneur with more than 20 years of demonstrated experience in scaling businesses from scratch.
- Areas of work include digital platform of healthcare and financial services.

Mr. Parimal Kumar Chattaraj

- Bachelor's in science, a post graduate diploma in management and a bachelor's in law
- Experience of over 30 years working as an entrepreneur, management professional and legal advisor
- Areas of work include contributing to business strategy, aligning employee skill to business, creating learning organisation, leadership development and organisation & HR solutions

Mrs. Abha Mittal

- Commerce graduate and holds a diploma in fashion designing
- Multiple years of experience working as a social worker and environmentalist
- Areas of work include NGOs and organic farming

Mrs. Rupanjana De


- FCS & post graduate qualifications in law and economics
- Has over 19 years of experience working as a corporate legal professional
- Areas of work include company law, legal compliance, management, corporate governance, Corporate Social Responsibility and quality control

Dr. Jayanta Nath Mukhopadhyaya

- He has 35 years of professional experience
- Mechanical engineer from IIT - BHU, Varanasi, MBA from IIM Calcutta, UGC NET qualified and PhD in Economics from Jadavpur University
- Has over 17 years of experience in industry working with leading companies like BOC India, IBP - Balmer Lawrie, Alghanim & SREI
- Presently Professor of Finance at Army Institute of Management and non-Executive Director at Vara Technology

Q4 & FY23 Key Financial Highlights


Revenue from Operations



Revenue

- ✓ Revenue for Q4FY23 stood at Rs. 311.5 crs as compared to Rs. 157.6 crs in Q4FY22, a **growth of +97.7%**
- ✓ Revenue for FY23 showed robust growth and **grew by +66.4 % to Rs. 1,036.9 crs**


Gross Profit



Gross Profit

- ✓ Gross Profit for Q4FY23 & FY23 stood at Rs. 23.8 crs & Rs. 76.5 crs respectively
- ✓ Gross Profit margins have increased during the year due to continuous focus on cost optimization, process improvement, increase in volume & digital technology.

EBITDA



EBITDA

- ✓ EBITDA for Q4FY23 & FY23 stood at Rs. **-12.8 crs** & Rs. **-46.8 crs** respectively

Q4 & FY23 Consolidated Profit & Loss Statement

Particulars (Rs. Crs)	Q4 FY23	Q4 FY22 (Restated)	Y-o-Y	Q3 FY23 (Restated)	Q-o-Q	FY23	FY22 (Restated)	Y-o-Y
Revenue from Operations	311.5	157.6	97.7%	279.8	11.3%	1,036.9	623.0	66.4%
Cost of Materials Consumed	287.7	148.0		258.3		960.4	582.5	
Gross Profit	23.8	9.6	147.9%	21.5	10.7%	76.5	40.5	88.9%
GP %	7.6%	6.1%		7.7%		7.4%	6.5%	
Employee Benefits Expense	12.2	16.7		11.3		45.3	43.9	
Other Expenses	24.4	12.2		21.0		78.0	53.7	
EBITDA	(12.8)	(19.3)	(33.7%)	(10.8)	18.5%	(46.8)	(57.1)	(18.0%)
EBITDA %	(4.1%)	(12.2%)		(3.9%)		(4.5%)	(9.2%)	
Other Income [#]	10.4	3.2		4.8		26.5	20.1	
Depreciation and Amortisation Expense	2.8	1.1		2.4		8.2	4.2	
EBIT	(5.2)	(17.2)	(69.8%)	(8.4)	(38.1%)	(28.5)	(41.2)	(30.8%)
Finance Costs	0.3	0.1		0.3		0.9	1.6	
Share from Associates	(26.3)	(5.2)		(23.8)		(84.9)	(5.2)	
Exceptional Items	(0.1)	(11.6)		0.0		(8.0)	1,157.5	
PBT	(31.9)	(34.1)	(6.5%)	(32.5)	(1.8%)	(122.3)	1,109.5	(111.0%)
Total Tax Expense	16.1	(8.0)		(6.2)		(22.8)	244.4	
Profit for the period	(48.0)	(26.1)	83.9%	(26.3)	82.5%	(99.5)	865.1	(111.5%)
PAT %	(15.4%)	(16.6%)		(9.4%)		(9.6%)	138.9%	

[#] Other Income includes financial service income

Consolidated Balance Sheet

Equity & Liabilities (Rs. Crs)	Mar-23	Mar-22 (Restated)
Equity Share Capital	31.8	31.8
Other Equity [#]	961.7	1,062.4
Total Equity	993.5	1,094.2
Non-Financial Liabilities		
(i) Other Financial Liabilities	8.2	3.5
Provisions	4.5	2.1
Tax Liabilities (Net)	24.1	17.9
Deferred Tax Liabilities (Net)	92.5	113.7
Total Non-Financial Liabilities	129.3	137.2
Financial Liabilities		
(i) Lease Liabilities	9.3	1.9
(ii) Trade Payables	57.0	33.0
Other Current Liabilities	16.7	11.5
Total Financial Liabilities	83.0	46.4
Total Equity & Liabilities	1,205.8	1,277.8

[#] Other Equity includes non-controlling interest of ₹ 240.2 Cr for FY 23 & ₹ 267.7 Cr. for FY 22


Assets (Rs. Crs)	Mar-23	Mar-22 (Restated)
Property, Plant and Equipment	68.1	57.2
Capital Work-in-Progress	1.0	0.4
Intangibles Assets	0.1	0.1
Goodwill on Consolidation	36.1	36.1
Tax Assets (Net)	4.4	2.3
Deferred Tax Assets	1.8	0.0
Investment Property	2.6	0.0
Other Non-Current Assets	45.8	24.9
Total Non-Current Assets	159.9	121.0
Inventories	180.8	113.6
Financial Assets		
(i) Investments	512.8	666.0
(ii) Trade Receivable	35.1	21.2
(iii) Cash and Cash Equivalent	31.7	13.0
(iv) Other Bank Balances	163.5	199.4
(v) Loans	8.0	9.6
Other Current Assets	114.0	134.0
Total Current Assets	1045.9	1,156.8
Total Assets	1205.8	1,277.8

Consolidated Cash Flow Statement

Particulars (Rs. Crs)	Mar-23	Mar-22
Cash Flow from Operating Activities		
Profit before Tax	(122.3)	1,109.5
Adjustment for Non-Operating Items	84.0	(1,151.0)
Operating Profit before Working Capital Changes	(38.3)	(41.5)
Changes in Working Capital	(70.2)	(52.7)
Cash Generated from Operations	(108.5)	(94.2)
Less: Direct Taxes paid	4.0	(112.9)
Net Cash from Operating Activities	(104.5)	(207.1)
Cash Flow from Investing Activities	124.1	219.5
Cash Flow from Financing Activities	(0.9)	(11.4)
Net increase/ (decrease) in Cash & Cash Equivalent	18.7	1.0
Cash & Cash Equivalents at the beginning of the period	13.0	12.0
Cash & Cash Equivalents at the end of the period	31.7	13.0

Annual Financial Highlights


Revenue from Operations



Revenue

- ✓ FY23 revenue stood at Rs. 1,037 crs as compared to Rs. 385 crs, **growth of +169%** from FY20

Gross Profit



Gross Profit

- ✓ FY23 gross profit **grew by +353%** to Rs. 77 crs as compared to Rs. 17 crs in FY20
- ✓ Gross margin for FY23 stood at **7.4%**.

Historical Consolidated Profit & Loss Statement

Particulars (Rs. Crs)	Mar-23	Mar-22 (Restated)	Mar-21	Mar-20	Mar-19
Revenue from Operations	1,036.9	623.0	540.0	384.0	215.6
Cost of Materials Consumed	960.4	582.5	492.5	366.9	199.5
Gross Profit	76.5	40.5	47.5	17.1	16.1
GP %	7.4%	6.5%	8.8%	4.5%	7.5%
Employee Benefits Expense	45.3	43.9	29.1	28.4	23.4
Other Expenses	78.0	53.7	40.9	45.4	33.1
EBITDA	(46.8)	(57.1)	(22.5)	(56.7)	(40.4)
EBITDA %	(4.5%)	(9.2%)	(4.2%)	(14.8%)	(18.7%)
Other Income [#]	26.5	20.1	11.6	4.5	6.6
Depreciation and Amortisation Expense	8.2	4.2	4.5	4.9	6.0
EBIT	(28.5)	(41.2)	(15.4)	(57.1)	(39.8)
Finance Costs	0.9	1.6	1.0	0.7	2.0
Share from Associates	(84.9)	(5.2)	0.0	0.0	0.0
Exceptional Items	(8.0)	1,157.5	0.0	0.3	0.0
PBT	(122.3)	1,109.5	(16.4)	(57.5)	(41.8)
Tax Expense	(22.8)	244.4	0.7	(5.4)	1.1
Profit for the year	(99.5)	865.1	(17.1)	(52.1)	(42.9)
PAT %	(9.6%)	138.9%	(3.2%)	(13.6%)	(19.9%)
EPS	(22.70)	197.04	(3.27)	(12.20)	(11.81)

[#] Other Income includes financial service income

Historical Consolidated Balance Sheet

Equity & Liabilities (Rs. Crs)	Mar-23	Mar-22 (Restated)	Mar-21	Mar-20	Mar-19	Assets (Rs. Crs)	Mar-23	Mar-22 (Restated)	Mar-21	Mar-20	Mar-19
Equity Share Capital	31.8	31.8	31.8	31.8	31.8	Property, Plant and Equipment	68.1	57.2	57.3	60.2	62.7
Other Equity #	961.7	1,062.4	197.6	214.4	168.6	Capital Work-in-Progress	1.0	0.4	0.1	0.0	0.8
Total Equity	993.5	1,094.2	229.4	246.2	200.4	Intangibles Assets	0.1	0.1	0.4	0.7	1.0
Non-Financial Liabilities						Goodwill on Consolidation	36.1	36.1	52.7	52.7	52.7
(i) Borrowings	0.0	0.0	0.0	0.0	0.0	Tax Assets (Net)	4.4	2.3	2.2	1.9	2.7
(ii) Other Financial Liabilities	8.2	3.5	1.5	1.4	0.9	Deferred Tax Assets	1.8	0.0	0.0	0.0	0.0
Provisions	4.5	2.1	1.9	1.6	0.9	Investment Property	2.6	0.0	0.0	0.0	0.0
Tax Liabilities (Net)	24.1	17.9	0.0	0.1	5.5	Other Non-Current Assets	45.8	24.9	18.7	18.2	11.9
Deferred Tax Liabilities (Net)	92.5	113.7	0.1	0.0	5.5	Total Non-Current Assets	159.9	121.0	131.4	133.9	131.8
Total Non-Financial Liabilities	129.3	137.2	3.5	3.0	7.3	Inventories	180.8	113.6	77.2	77.1	32.6
Financial Liabilities						Financial Assets					
(i) Borrowings	0.0	0.0	9.8	5.0	0.0	(i) Investments	512.8	666.0	43.4	55.8	35.9
(ii) Lease Liabilities	9.3	1.9	2.7	2.8	2.3	(ii) Trade Receivable	35.1	21.2	13.6	15.0	7.9
(iii) Trade Payables	57.0	33.0	38.6	50.2	14.3	(iii) Cash and Cash Equivalents	31.7	13.0	12.0	17.5	6.3
Other Current Liabilities	16.7	11.5	8.6	8.2	6.2	(iv) Other Bank Balances	163.5	199.4	0.8	0.8	0.3
Total Financial Liabilities	83.0	46.4	59.7	66.2	22.8	(v) Loans	8.0	9.6	8.2	8.9	11.6
Total Equity & Liabilities	1,205.8	1,277.8	292.6	315.5	230.5	Other Current Assets	114.0	134.0	6.0	6.7	4.1
						Total Current Assets	1,045.9	1,156.8	161.2	181.6	98.7
						Total Assets	1,205.8	1,277.8	292.6	315.5	230.5

Other Equity includes non-controlling interest

Historical Consolidated Cash Flow Statement

Particulars (Rs. Crs)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Cash Flow from Operating Activities					
Profit before Tax	(122.3)	1,109.5	(16.4)	(57.6)	(41.8)
Adjustment for Non-Operating Items	84.0	(1,151.0)	(3.2)	4.8	7.8
Operating Profit before Working Capital Changes	(38.3)	(41.5)	(19.6)	(52.8)	(34.0)
Changes in Working Capital	(70.2)	(52.7)	(9.9)	(38.5)	4.4
Cash Generated from Operations	(108.5)	(94.2)	(29.5)	(91.2)	(29.6)
Less: Direct Taxes paid	4.0	(112.9)	(1.0)	0.9	(0.4)
Net Cash from Operating Activities	(104.5)	(207.1)	(30.5)	(90.3)	(30.0)
Cash Flow from Investing Activities	124.1	219.5	21.4	(1.0)	(2.2)
Cash Flow from Financing Activities	(0.9)	(11.4)	3.7	102.5	26.3
Net increase/ (decrease) in Cash & Cash Equivalent	18.7	1.0	(5.4)	11.2	(5.9)
Cash & Cash Equivalents at the beginning of the period	13.0	12.0	17.5	6.3	12.2
Cash & Cash Equivalents at the end of the period	31.7	13.0	12.0	17.5	6.3

'Being Genuine' is Our Core Value

Nothing can be more Genuine
than our Mothers' Love

BEING GENUINE

OUR CORE VALUE

We ensure that all our
products and services are
100% Genuine.

 **SastaSundar**
GROUP
health & happiness

'Being Child' is Our Culture

'BEING CHILD'

IS OUR CULTURE

Like Child-
'Innovate',
'Don't Discriminate',
'Connect Emotionally' &
'Grow Everyday'.

 **SastaSundar**
GROUP
health & happiness



Company:

SastaSundar

SastaSundar Ventures Limited

CIN: L65993WB1989PLC047002

Mr. Pratap Singh – Company Secretary

Email Id : investors@sastasundar.com

www.sastasundarventures.com

Investor Relations Partner:



Orient Capital (a division of Link Group)

Ronak Jain

Ronak.jain@linkintime.co.in

+91 98209 50544

www.orientcap.com

Irfan Raeen

Irfan.raeen@linkintime.co.in

+91 97737 78669

Health & Happiness